Latest News in the pharma Industry

Research & Development

STA Pharma expands R&D team at is Changzhou site

STA Pharma expands R&D team at is Changzhou site

6 Feb 2017

By the end of 2017, company plans to increase to 230 process chemists and 70 analytical chemists.

Read more 
Amgen's Repatha significantly reduced the risk of cardiovascular events in FOURIER outcomes study

Amgen's Repatha significantly reduced the risk of cardiovascular events in FOURIER outcomes study

6 Feb 2017

Landmark Repatha cardiovascular outcomes study meets primary and key secondary endpoint.

Read more 
FDA accepts two sBLAs for Merck's Keytruda for metastatic urothelial cancer

FDA accepts two sBLAs for Merck's Keytruda for metastatic urothelial cancer

5 Feb 2017

Keytruda also receives Breakthrough Therapy Designation for second-line treatment.

Read more 
FDA approves BMS's Opdivo for bladder cancer

FDA approves BMS's Opdivo for bladder cancer

5 Feb 2017

Opdivo has now been approved in six tumour types in just over 2 years.

Read more 
Merck gets the thumbs up in Europe for Keytruda to treat patients with metastatic NSCLC

Merck gets the thumbs up in Europe for Keytruda to treat patients with metastatic NSCLC

2 Feb 2017

First anti-PD-1 therapy approved in Europe for previously untreated patients with metastatic NSCLC.

Read more 
Novartis' Votubia receives EU approval to treat refractory partial-onset seizures in patients with TSC

Novartis' Votubia receives EU approval to treat refractory partial-onset seizures in patients with TSC

31 Jan 2017

Decision marks the third TSC-related indication for Votubia in the EU.

Read more 
FDA approves Allergan's sNDA for Avycaz to include new Phase III data in patients with cUTI

FDA approves Allergan's sNDA for Avycaz to include new Phase III data in patients with cUTI

30 Jan 2017

New clinical data for Avycaz demonstrates efficacy in cUTI patients including those with infections due to resistant Gram-negative pathogens.

Read more 
First adalimumab biosimilar candidate recommended for EMA approval

First adalimumab biosimilar candidate recommended for EMA approval

29 Jan 2017

Amgen receives positive CHMP opinion for biosimilar adalimumab.

Read more 
J&J to acquire Acelion for $30 B with spin-out of new R&D company

J&J to acquire Acelion for $30 B with spin-out of new R&D company

29 Jan 2017

Actelion R&D unit to spin out into standalone company based and listed in Switzerland.

Read more 
X4 Pharma initiates clinical study of X4P-001 in combination with Opdivo

X4 Pharma initiates clinical study of X4P-001 in combination with Opdivo

28 Jan 2017

Combination studied as treatment for patients with advanced clear cell renal cell carcinoma.

Read more 
Non-opiate painkiller, AnestaGel, found superior in preclinical tests

Non-opiate painkiller, AnestaGel, found superior in preclinical tests

26 Jan 2017

AnestaGel uses a novel approach to delivering sustained-released analgesics into the target tissue via the Matrix, which is a tunable, biocompatible, and pH neutral platform.

Read more 
Axim Biotech enters IBS clinical trial for CanChew CBD chewing gum

Axim Biotech enters IBS clinical trial for CanChew CBD chewing gum

26 Jan 2017

Clinical trial is the first of its kind to treat IBS symptoms by cannabinoid-containing chewing gum.

Read more